RxDoctor Payments Data

Donald Holcomb, PA

Physician Assistant · Charleston, WVNPI 1073652335

Payments from drug & device makers

$2,873in general payments, 2019–2025

Across 184 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Acadia Pharmaceuticals Inc$325
  • Neurocrine Biosciences, Inc.$201
  • UCB, Inc.$182
  • Biohaven Pharmaceutical Holding Company Ltd.$137
  • AstraZeneca$114
  • plus $768 from 15 others

What the payments were for

  • Consulting fees$30010%
  • Food & beverage$2,45385%
  • Education$1204%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,873 in reported general payments places this provider in the 90th percentile of 833 physician assistant providers in West Virginia.

See all physician assistant providers in West Virginia

Medicare billing

Part B allowed, 2024
$23,891
Medicare patients
175
Services billed
324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine11$166,110
NuplazidPimavanserin Tartrate23$128,853
BriviactBrivaracetam49$74,935
UbrelvyUbrogepant36$72,040
VimpatLacosamide33$51,724
AptiomEslicarbazepine Acetate20$43,762
FycompaPerampanel24$42,172
Nurtec OdtRimegepant Sulfate31$36,402
Glatiramer Acetate11$29,568
ZonegranZonisamide11$28,315
Oxtellar XrOxcarbazepine14$25,227
Lacosamide130$24,762
RytaryCarbidopa/Levodopa15$23,405
XcopriCenobamate15$13,118
Levetiracetam322$12,959

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$57$166,11011 claims
Acadia Pharmaceuticals IncNuplazid$325$128,85323 claims
UCB, Inc.Briviact, Vimpat$182$126,65982 claims
AbbVieUbrelvy$1,146$72,04036 claims
PfizerNurtec Odt$17$36,40231 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$34$24,90233 claims
SK Life Science, Inc.Xcopri$83$13,11815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 833 physician assistant providers in West Virginia.

Other physician assistant in Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →